Timothy Mullett, MD, leaned toward his computer screen as he spoke, drowning out the sounds of the busy coffee shop behind him to get his message across.
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
The narrative spans four generations, highlighting the hereditary nature of breast cancer and its impact on family dynamics.
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring ...
After a recent study found Native Americans are 73% more likely to die from cancer than the general population, OU Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback